#OCT MACULAR TEST TRIAL#

Looking forward, the potential for longer-acting drugs, patient-administered therapies (e.g.

The physician review, interpretation and documentation of AI-based analyses will be billable every 30 days. In January 2020 the American Medical Association established three category III billing codes for reporting patient-initiated remote retinal OCT scans, facilitated by Notal Vision’s home-based OCT. In December 2018, the Notal Home OCT was granted Breakthrough Status by the FDA and selected to participate in FDA’s OCT Innovation Pilot program. If retinal fluid is detected, a report is generated by NOA and conveyed to the treating physician by the Notal Vision Monitoring Center, helping to reduce the time from fluid onset to the next treatment. Once a patient completes the test, a proprietary machine-learning algorithm, the Notal OCT Analyzer (NOA TM), performs an automated analysis.

#OCT MACULAR TEST TRIAL#

An ongoing US usability trial demonstrates that 90% of AMD patients can self-operate and generate analyzable images following a 2-minute tutorial (iAMD and eAMD >20/400 visual acuity) 1. The Notal Home OCT is a patient-friendly light-weight device designed for technician-free operation by nAMD patients from the comfort of their home. The Notal Home OCT is a first-of-its-kind artificial intelligence-enabled program for monitoring neovascular Age-related Macular Degeneration (nAMD) using a home-based Optical Coherence Tomography (OCT) device, which will complement current disease monitoring strategies by providing eye care providers. Today, doctors use OCT devices to image retinal structures during scheduled office examinations, providing valuable diagnostic information. Optical coherence tomography (OCT) is a noninvasive imaging technology widely adopted by eye care professionals to view retinal anatomy and assess the need for treatment of increasingly prevalent, and often age-related, eye diseases that lead to blindness.

Oct macular test